Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma.
Gail M GauvreauRoma SehmiChristopher S AmbroseJanet M GriffithsPublished in: Expert opinion on therapeutic targets (2020)
The position of TSLP at the top of the inflammatory cascade makes it a promising therapeutic target in asthma. Systemic anti-TSLP monoclonal antibody therapy with tezepelumab has yielded positive results in clinical trials to date, reducing exacerbations and biomarkers of inflammation in patients across the spectrum of inflammatory endotypes. Inhaled anti-TSLP is an alternative route currently under evaluation. The long-term safety and efficacy of TSLP blockade need to be evaluated.
Keyphrases
- chronic obstructive pulmonary disease
- monoclonal antibody
- oxidative stress
- clinical trial
- end stage renal disease
- cystic fibrosis
- lung function
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- allergic rhinitis
- bone marrow
- stem cells
- randomized controlled trial
- air pollution
- open label
- patient reported
- double blind